Permeability of the Perindopril Arginine under In Vitro Conditions across Caco-2 Monolayer and Biomimetic Phospholipid Membrane
| cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtual.author-orcid | 0000-0002-4385-0051 | |
| cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtualsource.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtualsource.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtualsource.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtualsource.author-orcid | 48ec8e95-930e-4be2-b47a-b597e5d7440b | |
| cris.virtualsource.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtualsource.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtualsource.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| dc.abstract.en | Perindopril arginine (PA) as an angiotensin-converting enzyme (ACE) inhibitor is widely used in cardiovascular diseases, especially in systemic hypertension and heart failure. Although the pharmacokinetics of PA are well documented, there is no available detailed data on its permeation in in vitro conditions. The present study aimed to assess the transport of PA across both biological membranes and artificial biomimetic ones. For the determination of PA transport, the Caco-2 cell line was selected as a reliable in vitro model of gastrointestinal biological barriers. Additionally, a novel 96-well plate with phospholipid membrane PermeaPad was used to evaluate the transport of PA by passive diffusion. We confirmed that PA is relatively poorly permeable across the Caco-2 monolayer. The permeability results obtained from the non-cell-based model demonstrated higher transport of PA as compared to that of Caco-2. Thus, PA transport across the biological membranes might be suggested to be regulated by the membrane transporters. | |
| dc.affiliation | Wydział Nauk o Żywności i Żywieniu | |
| dc.affiliation.institute | Katedra Biotechnologii i Mikrobiologii Żywności | |
| dc.contributor.author | Kus, Marta | |
| dc.contributor.author | Gorniak, Klaudia | |
| dc.contributor.author | Czaklosz, Piotr | |
| dc.contributor.author | Olejnik, Anna | |
| dc.contributor.author | Skupin-Mrugalska, Paulina | |
| dc.contributor.author | Ibragimow, Izabela | |
| dc.contributor.author | Piotrowska-Kempisty, Hanna | |
| dc.date.access | 2026-03-11 | |
| dc.date.accessioned | 2026-03-11T08:56:49Z | |
| dc.date.available | 2026-03-11T08:56:49Z | |
| dc.date.copyright | 2022-03-30 | |
| dc.date.issued | 2022 | |
| dc.description.abstract | <jats:p>Perindopril arginine (PA) as an angiotensin-converting enzyme (ACE) inhibitor is widely used in cardiovascular diseases, especially in systemic hypertension and heart failure. Although the pharmacokinetics of PA are well documented, there is no available detailed data on its permeation in in vitro conditions. The present study aimed to assess the transport of PA across both biological membranes and artificial biomimetic ones. For the determination of PA transport, the Caco-2 cell line was selected as a reliable in vitro model of gastrointestinal biological barriers. Additionally, a novel 96-well plate with phospholipid membrane PermeaPad was used to evaluate the transport of PA by passive diffusion. We confirmed that PA is relatively poorly permeable across the Caco-2 monolayer. The permeability results obtained from the non-cell-based model demonstrated higher transport of PA as compared to that of Caco-2. Thus, PA transport across the biological membranes might be suggested to be regulated by the membrane transporters.</jats:p> | |
| dc.description.accesstime | at_publication | |
| dc.description.bibliography | il., bibliogr. | |
| dc.description.finance | publication_nocost | |
| dc.description.financecost | 0,00 | |
| dc.description.if | 4,6 | |
| dc.description.number | 7 | |
| dc.description.points | 140 | |
| dc.description.version | final_published | |
| dc.description.volume | 27 | |
| dc.identifier.doi | 10.3390/molecules27072232 | |
| dc.identifier.issn | 1420-3049 | |
| dc.identifier.uri | https://sciencerep.up.poznan.pl/handle/item/7774 | |
| dc.identifier.weblink | https://www.mdpi.com/1420-3049/27/7/2232 | |
| dc.language | en | |
| dc.relation.ispartof | Molecules | |
| dc.relation.pages | art. 2232 | |
| dc.rights | CC-BY | |
| dc.sciencecloud | nosend | |
| dc.share.type | OPEN_JOURNAL | |
| dc.subject.en | perindopril arginine | |
| dc.subject.en | permeability | |
| dc.subject.en | Caco-2 monolayer | |
| dc.subject.en | PermeaPad® 96-well plate | |
| dc.subject.en | simple diffusion | |
| dc.subject.en | intestinal absorption | |
| dc.title | Permeability of the Perindopril Arginine under In Vitro Conditions across Caco-2 Monolayer and Biomimetic Phospholipid Membrane | |
| dc.title.volume | Special Issue Drug Delivery Systems for Overcoming the Biological Barriers and Improving the Therapeutic Effect | |
| dc.type | JournalArticle | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 7 | |
| oaire.citation.volume | 27 |